Charles River Laboratories International, Inc.

NYSE:CRL

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

🔍 Research & Consulting

Location

United States

Market Cap

USD 7.33 B

Share Price

USD 148.93

Avg Daily Volume

989,171

Change (1 day)

0.13%

Change (1 year)

-25.89%

Change (YTD)

-19.32%

Charles River Laboratories International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending June 28, 2025: 13.12%

Charles River Laboratories International, Inc. EBITDA Margin is 13.12% for the Trailing 12 Months (TTM) ending June 28, 2025, a -46.84% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Charles River Laboratories International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending June 29, 2024 was 24.67%, a -3.44% change year over year.
Charles River Laboratories International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending July 01, 2023 was 25.55%, a 5.01% change year over year.
Charles River Laboratories International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending June 25, 2022 was 24.33%, a -5.11% change year over year.
Charles River Laboratories International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending June 26, 2021 was 25.64%, a 14.03% change year over year.